Tiotropium Respimat inhaler and the risk of death in COPD

Robert A Wise; Antonio Anzueto; Daniel Cotton; Ronald Dahl; Theresa Devins; Bernd Disse; Daniel Dusser; Elizabeth Joseph; Sabine Kattenbeck; Michael Koenen-Bergmann; Gordon Pledger; Peter Calverley; TIOSPIR Investigators; Lorcan McGarvey

doi:10.1056/NEJMoa1303342

Tiotropium Respimat inhaler and the risk of death in COPD

Robert A Wise, Antonio Anzueto, Daniel Cotton, Ronald Dahl, Theresa Devins, Bernd Disse, Daniel Dusser, Elizabeth Joseph, Sabine Kattenbeck, Michael Koenen-Bergmann, Gordon Pledger, Peter Calverley, TIOSPIR Investigators, Lorcan McGarvey

Research output: Contribution to journal › Article › peer-review

318 Citations (Scopus)

Abstract

Tiotropium delivered at a dose of 5 μg with the Respimat inhaler showed efficacy similar to that of 18 μg of tiotropium delivered with the HandiHaler inhalation device in placebo-controlled trials involving patients with chronic obstructive pulmonary disease (COPD). Although tiotropium HandiHaler was associated with reduced mortality, as compared with placebo, more deaths were reported with tiotropium Respimat than with placebo.

Original language	English
Pages (from-to)	1491-501
Number of pages	11
Journal	New England Journal of Medicine
Volume	369
Issue number	16
DOIs	https://doi.org/10.1056/NEJMoa1303342
Publication status	Published - 17 Oct 2013

Keywords

Administration, Inhalation
Aged
Aged, 80 and over
Bronchodilator Agents
Double-Blind Method
Female
Forced Expiratory Volume
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Nebulizers and Vaporizers
Pulmonary Disease, Chronic Obstructive
Risk
Scopolamine Derivatives
Spirometry

Access to Document

10.1056/NEJMoa1303342

Cite this

@article{372902ae5265423daebcfd56a62cf089,

title = "Tiotropium Respimat inhaler and the risk of death in COPD",

abstract = "Tiotropium delivered at a dose of 5 μg with the Respimat inhaler showed efficacy similar to that of 18 μg of tiotropium delivered with the HandiHaler inhalation device in placebo-controlled trials involving patients with chronic obstructive pulmonary disease (COPD). Although tiotropium HandiHaler was associated with reduced mortality, as compared with placebo, more deaths were reported with tiotropium Respimat than with placebo.",

keywords = "Administration, Inhalation, Aged, Aged, 80 and over, Bronchodilator Agents, Double-Blind Method, Female, Forced Expiratory Volume, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Nebulizers and Vaporizers, Pulmonary Disease, Chronic Obstructive, Risk, Scopolamine Derivatives, Spirometry",

author = "Wise, {Robert A} and Antonio Anzueto and Daniel Cotton and Ronald Dahl and Theresa Devins and Bernd Disse and Daniel Dusser and Elizabeth Joseph and Sabine Kattenbeck and Michael Koenen-Bergmann and Gordon Pledger and Peter Calverley and {TIOSPIR Investigators} and Lorcan McGarvey",

year = "2013",

month = oct,

day = "17",

doi = "10.1056/NEJMoa1303342",

language = "English",

volume = "369",

pages = "1491--501",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "16",

}

TY - JOUR

T1 - Tiotropium Respimat inhaler and the risk of death in COPD

AU - Wise, Robert A

AU - Anzueto, Antonio

AU - Cotton, Daniel

AU - Dahl, Ronald

AU - Devins, Theresa

AU - Disse, Bernd

AU - Dusser, Daniel

AU - Joseph, Elizabeth

AU - Kattenbeck, Sabine

AU - Koenen-Bergmann, Michael

AU - Pledger, Gordon

AU - Calverley, Peter

AU - TIOSPIR Investigators

AU - McGarvey, Lorcan

PY - 2013/10/17

Y1 - 2013/10/17

N2 - Tiotropium delivered at a dose of 5 μg with the Respimat inhaler showed efficacy similar to that of 18 μg of tiotropium delivered with the HandiHaler inhalation device in placebo-controlled trials involving patients with chronic obstructive pulmonary disease (COPD). Although tiotropium HandiHaler was associated with reduced mortality, as compared with placebo, more deaths were reported with tiotropium Respimat than with placebo.

AB - Tiotropium delivered at a dose of 5 μg with the Respimat inhaler showed efficacy similar to that of 18 μg of tiotropium delivered with the HandiHaler inhalation device in placebo-controlled trials involving patients with chronic obstructive pulmonary disease (COPD). Although tiotropium HandiHaler was associated with reduced mortality, as compared with placebo, more deaths were reported with tiotropium Respimat than with placebo.

KW - Administration, Inhalation

KW - Aged

KW - Aged, 80 and over

KW - Bronchodilator Agents

KW - Double-Blind Method

KW - Female

KW - Forced Expiratory Volume

KW - Humans

KW - Kaplan-Meier Estimate

KW - Male

KW - Middle Aged

KW - Nebulizers and Vaporizers

KW - Pulmonary Disease, Chronic Obstructive

KW - Risk

KW - Scopolamine Derivatives

KW - Spirometry

U2 - 10.1056/NEJMoa1303342

DO - 10.1056/NEJMoa1303342

M3 - Article

C2 - 23992515

SN - 0028-4793

VL - 369

SP - 1491

EP - 1501

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 16

ER -

Tiotropium Respimat inhaler and the risk of death in COPD

Abstract

Keywords

Access to Document

Fingerprint

Cite this